Author:
Appelboom Thierry,Maes Nathalie,Albert Adelin
Abstract
This retrospective observational study summarizes the experiences of 820 patients treated with a new Curcuma extract (Flexofytol®, 4-6 capsules per day), for more than 6 months for various forms of painful osteoarthritis. These experiences were reported by 110 Belgian general practitioners via a questionnaire that included quality-of-life parameters for assessing patient experience. Data were submitted to an independent statistician for analysis. Within the first 6 weeks, Flexofytol® improved patient pain, articular mobility, and quality of life. Excellent tolerance was reported, and more than half of these patients were able to discontinue analgaesic and anti-inflammatory drugs. Patient satisfaction was confirmed by their decision to maintain Flexofytol® therapy for more than 6 months. These data must be confirmed with randomized controlled studies. We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits for articular mobility, pain, and quality of life.
Publisher
Bentham Science Publishers Ltd.
Reference15 articles.
1. Hatcher H, Planalp R, Cho J , et al.
Curcumin from ancient medicine to current clinical trials.
Cell Mol Life Sci
2008;
65
: 1631-52.
2. Srinivasan K.
Antioxidant potential of spices and their active constituents.
Crit Rev Food Sci Nutr
2014;
54
: 352-72.
3. Shehzad A, Rehman G, Lee YS.
Curcumin in inflammatory diseases.
Biofactors
2013;
39
: 69-77.
4. Jurenka JS.
Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa a review of preclinical and clinical research.
Altern Med Rev
2009;
14
: 141-53.
5. Prasad S, Gupta SC, Tyagi AK, Aggarwal BB.
Curcumin, a component of golden spice form bedside to bench and back.
Biotechnol Adv
2014;
32
(6)
: 1053-64.
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献